[ad_1]
BioNTech will have access to Sanofi’s manufacturing facilities to produce more than 125 million doses of the vaccine that will be destined for countries of the European Union
BioNTech will have access to Sanofi’s manufacturing facilities to produce more than 125 million doses of the vaccine that will be destined for countries of the European Union
3 ‘reading
It’s a turning point in the race to vaccinate as many people as possible against Covid, even if the positive effects won’t be seen before the summer. The French pharmaceutical giant Sanofi has reached an agreement with the German company BioNTech that together with the American Pfizer has developed the first vaccine against Covid commercialized in the EU and the most controversial in the world, so much so that the delay in deliveries has enraged to Italy. threatens legal action, Sweden threatens to suspend payments and the entire European Union with the warnings of the president of the EU Commission, Ursula von der Leyen.
Now Sanofi goes out into the field, offering its production lines to produce the Pfizer vaccine, the development of which was only possible thanks to the research of the German BioNTech.
Loading…
And in fact it is BioNTech that will have access to Sanofi’s production facilities to produce more than 125 million doses of the vaccine that will be destined for the countries of the European Union. Initial supplies will come from Sanofi’s German production plant in Frankfurt. The first doses will arrive in summer.
A Franco-German axis of vaccines
This decision also sanctions in some way a surrender of Sanofi itself which is lagging behind with the development of its vaccine – development started together with Gsk which is based on a viral vector vaccine and therefore the same technology as that of AstraZeneca. However, unlike the American Merck, which abandoned the work on the development of vaccines because the tests were unsuccessful, Sanofi makes an alliance with BioNTech: and one cannot fail to see in this agreement a political strategy of the EU: the first doses are intended exclusively for EU Citizens. A Franco-German axis of vaccines, you might say.
Just a few months ago, Sanofi had been scolded by President Macron himself, as well as with the summons of the CEO by the French Prime Minister, because he had promised to put the US before France and therefore the EU in delivery of the doses of your vaccine if it were to be marketed. Things turned out differently.
